Antibody-drug Conjugates or ADCs are highly targeted biopharmaceutical drugs that combine monoclonal antibodies specific to surface antigens present on particular tumor cells with highly potent anti-cancer agents linked via a chemical linker. The linker plays a key role in determining the pharmacokinetic properties, therapeutic index, selectivity and the overall success of the ADC.